Science and Research

ClairleafTM: A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis.

A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)

Study details
Study-ID: NCT05846230, 2023-503290-38-00
Study-ID: NCT05846230, 2023-503290-38-00
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, BREATH, CPC-M, BIH / Charité - Associated Partner
DZL Participating Sites: ARCN, BREATH, CPC-M, BIH / Charité - Associated Partner
Start Date: 16.10.2023
Completion Date: 30.03.2026
Status: Closed
Status: Closed
DZL recruiting center, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.